HIF-1α polymorphism linked to lower metabolic syndrome odds in HIV patients on ART

This cross-sectional study examined the association between the HIF-1α rs11549465 (C1772T) polymorphism and metabolic syndrome in 121 people living with HIV on antiretroviral therapy across multiple centers. The primary outcome was metabolic syndrome, which was identified in 47 participants (38.8%). The minor T allele frequency was 24%. The analysis found that the T allele and CT/CT+TT genotypes were associated with a significantly lower odds of metabolic syndrome, though the specific odds ratio, confidence intervals, and exact p-value were not reported.

Safety and tolerability data were not reported in the study. The cross-sectional design is a key limitation, as it captures data at a single timepoint and cannot establish causality or temporal sequence between the genetic polymorphism and metabolic syndrome development.

Other important limitations include the lack of reported effect size measures (e.g., odds ratio) and confidence intervals for the main association, incomplete p-value reporting, and an unspecified comparator group. The study population was limited to 121 individuals. The practice relevance of these findings is restrained; they represent a preliminary genetic association observed in a specific, cross-sectional HIV cohort and do not support clinical testing or intervention at this stage.